18.12.13 Kirana (SCALESVaidakis)

KAdkc kAivikq ck1qoq 1q
ocoudAikq uoAci1oupyd oc
vpc kdi yuvdkc
!"# $%&'(), MSc, PHD, Hon MJCSM
*%+,-./,0 1/23)0-425,-./,0
!6789#,(7:; 8%(2&/'9#0
$<(9&,% 425,%)-7:;0 :)7 =()6)&)/>/7:;0 1/23)0 =.?.@.
www.imop.gr
EPOTHMATA
MEPOZ A Kotovomvto to yvmotk nro
1. T rvo q or{ouoKkq uyro;
2. T npoyotrrto q or{ouoKkq otpkq;
3. Hm yvrto q yvmoq tmv or{ouoKkmv npoKqtmv;
4. Hoo rvo to kptqpo o{oKyqoq tq 0rponro;
MEPOZ B Book op rpyoKrmv
1. Hm nopov vo pqoonoq0ov to rpyoKro otqv ko0qrpvq kKvkq
np{q;
2. Hoo to guortpk opoktqpotk tmv rpyoKrmv;
3. Hm 0o rnK{our to rpyoKro o;
4. Hoo to oqovtktrpo rpyoKro otq or{ouoKkq uyro;
MEPOZ F H ropoyq tou otqv kKvkq np{q
1. Hopryo 1
2. Hopryo 2
3. Hopryo 3
EPOTHMATA
5. Hm nopov vo pqoonoq0ov to rpyoKro otqv ko0qrpvq
6. kKvkq np{q;
10. Hopryo 1
11. Hopryo 2
12. Hopryo 3
Health
Health is a state of complete physical,
mental and social well-being and not
merely the absence of disease or infirmity.
Sexual Health
Sexual health is a state of physical, emotional,
mental and social well-being in relation to
sexuality; it is not merely the absence of disease,
dysfunction or infirmity.
http://www.who.int/reproductive-health/gender/sexualhealth.html
mental
social
physical
emotional social
mental physical
Sexual
function
Sexual
education
Sexual
behavior
Sexual
relation-
ships
SEXUALITY
SexuallLy ls a cenLral aspecL of
belng human LhroughouL llfe
and encompasses:
! sex,
! gender ldenuues and roles,
! sexual orlenLauon,
! erouclsm,
! pleasure,
! lnumacy and
! reproducuon.
SexuallLy ls experlenced and expressed ln:
" LhoughLs,
" fanLasles,
" deslres,
" bellefs,
" amLudes,
" values,
" behavlours,
" pracuces,
" roles and
" relauonshlps.
Whlle sexuallLy can lnclude all of Lhese
dlmenslons, noL all of Lhem are always
experlenced or expressed.
HUMAN
SEXUALITY
Sexuality is influenced by the
interaction of multiple factors:
1
biological
2
psychological
3
social
4
economic
5
political
6
cultural
7
ethical
8
legal
9
historical
10
religious
11
spiritual
EPOTHMATA
5. Hm nopov vo pqoonoq0ov to rpyoKro otqv ko0qrpvq
kKvkq np{q;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
Definition of Sexual Medicine
European Academy for Sexual Medicine (EASM)
" Sexual medicine is the branch of medicine concerned with human sexuality and its disorders.
" Sexual medicine attempts to improve sexual health through the prevention, diagnosis, treatment, and
rehabilitation of conditions or diseases that involve:
! sexual function
! sexual and/or partnership experience and behaviour
! gender identity
! sexual trauma and its consequences.

" Sexual medicine takes into account the individual and couple dimension
as well as the knowledge and methods of medical, psychological and social sciences.
It recognizes that many of the conditions or disorders may be caused by other medical conditions
and/or their treatment.

http://www.essm.org/easm/scope.asp
EASM Board of Trustees
John Pryor (UK)
Members:
John Bancroft (UK)
Hartmut Bosinski (Germany)
Ian Eardley (UK)
Walter Everaerd (The Netherlands)
Kerstin Fugl-Mayer (Sweden)
Marc Ganem (France)
Dimitrios Hatzichristou (Greece)
Robert Porto (France)
Gorm Wagner (Denmark)
Definition of Clinical Sexology
Hatzichristou D, Kirana PS, Rosen R, Definitions and Principles in the
Practice of Clinical Sexology, in Kirana et al (eds); EFS and ESSM Syllabus
of Clinical Sexology, Medix, Amsterdam, 2013
Clinical sexology focuses on psychological, behavioral and cultural
aspects of sexual health and illness, while acknowledging their
interplay with biomedical aspects that are well understood by
medical science.
Clinical sexology integrates biomedical information with current
psychological knowledge in order to improve sexual health and well-
being through the prevention, diagnosis, treatment, and rehabilitation
of concerns, conditions or diseases that involve or affect:
sexual function,
sexual and/or partnership experience and behavior,
gender identity, and
sexual trauma and its consequences.
EPOTHMATA
np{q;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
3 Apc Aidcipioq 1v
ZcoudAikv AuoAci1oupyiv
!"#$%&&'$( ) )*+,)-."# .#- /$0)-1, ) %2/$( $.(- *#3'.'$',1
*"#$/"#&1 .(4 '/."',14 *"56(4

72/"#&1 .8- /"9:- .(4 .),("'8%-(4 '/."',14 (evidence-based
medicine) !"# $%&'()!# *+% ,-.+/-0+

;"1$( ,#'-14 *"#$%&&'$(4 $.(- /6'#3<&($( ,/' 0)"/*)+/ .8-
$)6#=/3',:- *"#>3(5.8- .8- /%()7:A( :)7 9>( )(B&A(
Aci1q1c HoAi1ioikq
Hpoodpoyq
# &-:$( )*'?('#3#&+/4 ,/' 0)"/*)=.',14 )*+?"/$(4 $) 533)4
*#3'.'$',%4 #5?)4.
# &-:$( .#= *:4 *#3'.'$',#+ */"5&#-.)4 )*(")5@#=- .#- ."<*#
$,%A(4 ,/' $=*)"'2#"54
# .# ,#'-8-',< *)"'>533#- ?'/>+8$(4 5338- *#3'.'$',:- #5?8-
# /-/&-:"'$( .8- ?',:- /4 $.)")#.B*8-
# ?=-/.<.(./ -/ &'-</$.) ,/./-#(.#+
# )=)3'6+/ ,/' )2)=").',<.(./
Seeleman C, et al. Med Educ. 2009;43(3):229-37
Evidence-Based Medicine
Tckqpiocvq Id1pikq
! Zuvdivc1ikq
! Zdqq
! Mc ovcoq
Xpqoq 1q kdA1cpq
1ckqpiooq o1qv
dioAyqoq kdi
qpov1id 1ou do0cvo
Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS: Evidence based medicine: what it is and what it isnt. BMJ 1996;312:71-2.
A unified management approach
in evaluating and treating
sexual problems in
both men and women
The International Consultation
in Sexual Medicine
algorithm
ICSM-4
EPOTHMATA
5. Hm nopov vo pqoonoq0ov to rpyoKro otqv ko0qrpvq kKvkq np{q;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
FOLLOW-UP Strategy
Adjustment to treatment
Sexual satisfaction
Tailoring treatment
Sexual function status
Changes in health status
Continuing education
Follow-up patients
Modified from D. Hatzichristou, IJIR 2001
Acceptance of treatment
(patient/partner)
Satisfaction with treatment
Alternative treatment options
Relationship
Sexual intimacy
Partner satisfaction
Sexual life satisfaction
Patients needs
Partners needs
EPOTHMATA
np{q;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
EPOTHMATA
np{q;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
Kd1Aoyo dvdqop (Checklists) vs
KAdkc
Kd1Aoyoi dvdqop (Checklists)
! Checklists 9"($'#*#'#B-./' $.( ,3'-',1 *"56( &'/ screening
! C&;/,&,0 )-.#*'$<4 *"#>3(5.8-
Brief Sexual
Symptom
Checklist
for men

1. 7+$.) ',/-#*#'(%-#4 ) .(- $)6#=/3',1 $/4 3)'.#="&+/;
$ C/'
$ D9'
=( .+7, 6)&):)-A )6)(9;892 970 6)&):'9> 2&>9;8270

2. !<$# 9"#-',< ?'5$.(/ ?)- )+$.) ',/-#*#'(%-#4 ) .(-
$)6#=/3',1 $/4 3)'.#="&+/;
..... (qvs)

4. Od 0/ds vd ouqqoss d 0dd du s ov yidp
od;
Ndi Oi
3a Hoo npKqo/ to ovtrtmn(rtr r tqv or{ouoKkq oo
Krtoupyo (vo q nrpootrpo)
$ E//siq q siooq osoud/ikq si0uid
$ Hp/qd ooq
$ Hpopq skospioq kd qv sdq
$ Kd0uopqoq q uoko/id oqv skospioq q ov opydo
$ Hvo kd qv osoud/ikq sdq
$ Kq ou ou kd qv sdq
$ A//o: ....................
3. Hoio d d dpdvo od svo/si spioospo;
1 2 3 4 5 6 7
Brief Sexual
Symptom
Checklist
for Women

1. 7+$.) ',/-#*#'(%-( ) .(- $)6#=/3',1 $/4 3)'.#="&+/;
$ C/'
$ D9'
=( .+7, 6)&):)-A )6)(9;892 970 6)&):'9> 2&>9;8270

2. !<$# 9"#-',< ?'5$.(/ ?)- )+$.) ',/-#*#'(%-#4 ) .(-
$)6#=/3',1 $/4 3)'.#="&+/;
..... (qvs)

4. Od 0/ds vd ouqqoss d 0dd du s ov yidp
od;
Ndi Oi
3o Hoo npKqo/ to ovtrtmn(rtr r tqv or{ouoKkq oo
Krtoupyo (vo q nrpootrpo)
$ 1 E//siq q siooq osoud/ikq si0uid
$ 2 Msiovq dio0qoq od ysvvqik pydvd
$ 3 Msiovq ypdvoq oov k/o
$ 4 Auoko/id sisuq opydoo
$ 4 Hvo kd qv osoud/ikq sdq
$ 5 A//o: ............

3. Which problem is most bothersome (circle) 1 2 3 4 5
KAdkc
! !#$#.',#*#'#B- .(- *3("#2#"+/ *#= 3/>5-#=) /*<
.#- /$0)-1
! Cut-offs
! ;"($'#*#'#B-./' &'/ .(- /6'#3<&($( .(4
/*#.)3)$/.',<.(./4 (*"'-- ).5 0)"/*)+/)
! !/"%9#=- )'4 >50#4 /6'#3<&($( .#= /$0)-#B4.
! !"%*)' -/ )+-/' *#3=?'5$././ ,/.5 .# ?=-/.<-.
EPOTHMATA
np{q;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
Bdoik quoc1pik dpdk1qpio1ik
cpydAcv yid 1qv ocoudAikq
Aci1oupyd

! E6'#*'$.+/ (reliability): FA(31 )$8.)"',1 $=-#91 (cronbach a > .50) ,/'Test-Retest
! 7&,="<.(./
- G'5,"'$(4 (3)'.#="&',#B vs. ?=$3)'.#="&',#B)
- 7=/'$0($+/ $) 0)"/*)=.',%4 /33/&%4
- HB&,3'$( ) 533/ )"&/3)+/
! H=-.#+/- G'5",)'/
! G'/98"'$<4 2B3#=
! G(#$')=%-)4 -<")4
LEVEL OF EVIDENCE
International Consultation in Sexual Medicine
Level 1 evidence (incorporates Oxford 1a, 1b) involves meta-anaylsis of trials (RCTs) or a
good quality randomized controlled trial.

Level 2 evidence (incorporates Oxford 2a, 2b and 2c) includes low quality RCT (e.g. < 80%
follow up) or meta-analysis (with homogeneity) of good quality prospective cohort
studies. These may include a single group when individuals who develop the condition are
compared with others from within the original cohort group. There can be parallel cohorts, where
those with the condition in the first group are compared with those in the second group.

Level 3 evidence (incorporates Oxford 3a, 3b and 4) includes good quality retrospective
case-control studies where a group of patients who have a condition are matched appropriately
(e.g. for age, sex etc) with control individuals who do not have the condition.

Level 4 evidence includes expert opinion where the opinion is based not on evidence but on
first principles (e.g. physiological or anatomical) or bench research.
Rec
Grades of Recommendation
Grade A recommendation usually depends on consistent level 1 evidence and often
means that the recommendation is effectively mandatory and placed within a clinical care
pathway. However, there will be occasions where excellent evidence (level 1) does not lead
to a Grade A recommendation, for example, if the therapy is prohibitively expensive,
dangerous or unethical.
Grade A recommendation can follow from Level 2 evidence. However, a Grade A
recommendation needs a greater body of evidence if based on anything except Level 1
evidence
Grade B recommendation usually depends on consistent level 2 and or 3 studies, or
majority evidence from RCTs.
Grade C recommendation usually depends on level 4 studies or majority evidence
from level 2/3 studies or Dephi processed expert opinion.
Grade D No recommendation possible would be used where the evidence is
inadequate or conflicting and when expert opinion is delivered without a formal analytical
process, such as by Dephi.
EPOTHMATA
np{q;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
H 0d cniAcouc 1o kd1AAqAo
cpydAco
! I/0#"+$.) ,/' &"5A.) .' 0%3).) -/ )."1$).) ,/' *#B 0%3).) -/ .#
9"($'#*#')+$.).
! J) *#'#=4 533#= ."<*#=4 *#")+.) -/ *).B9).) .# $,#*< $/4, ,/' .' *"#$0%.)' .#
)"&/3)+#.
! I5-.) '/ 3+$./ /*< *'0/-5 )"&/3)+/ ($=>#=3)=.)+.) 533#=4 )'?',#B4 1 ,5-).)
/-/@1.($( $.# www.pubmed.org $B28-/ ) .# $,#*< $/4.
! K5>).) =*<A( .( ?'/0)$'<.(./ ,/' .# *'0/-< ,<$.#4 (#',#-#',< ,/' ?'5",)'/).
! G'/>5$.) *"#$),.',5 ./ A=9#)."',5 9/"/,.("'$.',5 .#= )"&/3)+#=.
! H,)2.)+.) *53' /- ./'"'5@)' ) .# $,#*< $/4 ,/' *'0/-%4 /-.'?"5$)'4 .8- =*#,/
8-.
! H=*3(":$.) .# #' +?'#' ,/' #' $=-)"&5.)4 $/4!
! L)>/'80)+.) <.' %9).) ,/./-#1$)' *:4 &+-)./' .# scoring ,/' ( )"(-)+/ .8-
/*#.)3)$5.8-!
www.imop.gr
Mc0oo yAooikq npoodpoyq
! C/ >)>/'80#B) <.' .# *"8.<.=*# )"&/3)+# )+-/' 78,B"(), ) .# )./2"/$%-#

! GB# .B*#' '$#?=-/+/4:
H(/$'#3#&',1 '$#?=-/+/: /,"'>14 ).52"/$(
M--#'#3#&',1 '$#?=-/+/: ./ )"8.1/./ -/ &+-#-./' ,/./-#(.5 ) .# +?'# ."<*#
$.'4 ?B# ?'/2#").',%4 &3:$$)4.
Mc0oo yAooikq npoodpoyq

ORIGINAL INSTRUMENT
FIRST FORWARD TRANSLATION SECOND FORWARD TRANSLATION
RECONCILIATION
FIRST BACKWARD TRANSLATION SECOND BACKWARD TRANSLATION
BACK TRANSLATION REVIEW PROCESS
PILOT-TESTING
PILOT-TESTING REVIEW AND FINALIZATION
EPOTHMATA
np{q;
7. Hm 0o rnK{rtr to rpyoKro oo;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
Committee 6:
Clinical Evaluation & Scales
Men & Women
Committee Members:
Chairs: D. Hatzichristou (GR), R. Rosen (USA)
L. Derogatis (USA)
W. Y. Low (Malaysia)
E. Meuleman (NL)
M. OLeary (USA)
M. Sotomayor (Mexico)
T. Symonds (UK)
A. Overview and basic principles of sexual evaluation
B. Overview of standardized sexual function scales and questionnaires, as
well as outcome (HQL, treatment satisfaction) measures.
Tykupd EpydAcd AioAyqoq 1q
ZcoudAikq Aci1oupyd Fuvdikv
kdi Avpv
Changes in Sexual Functioning
Questionnaire (CSFQ)

! sexual desire-interest,
! sexual desire-frequency,
! sexual pleasure,
! sexual arousal/excitement,
! orgasm/completion
Total score- overall sexual function
Long version=36 men, 34 women, 14 short version

Kddoksuoqks yid vd svoisi !""!#$% oq osoud/ikq
/sioupyid sdiid d0qosov, .. kd0/iq, q pdkd, ..
SSRIs. Esi pqoiooiq0si sksvo os k/ivik s/s.
N / O
Grade B and Level 3
Derogatis Interview for Sexual
Functioning (DISF-SR)
! sexual cognition/fantasy,
! sexual arousal,
! sexual behavior/experience,
! orgasm, and
! sexual drive/relationship

Total score- quality of sexual functioning
Self report= 25 items

Ypsi kdi os opq qi- oqvq ouvvsuq kdi os koio
d0 dio/oysi i osi osoud/ikq dvdkpioq kd Masters
& Johnson. Avd/sdi dv spoqoq, uok/idkd, kdi ouvo/ik okop.
N / O
Grade B and Level 3
Golombok Rust Inventory of
Sexual Satisfaction (GRISS)
premature ejaculation
impotence
avoidance
non-sensuality
dissatisfaction
anorgasmia
vaginismus
avoidance
nonsensuality
dissatisfaction
Men-28 items
Women-28 items

Zsioqks yid vd
dio/oysi osoud/ik
po/qdd os
&'(#)*+!.

Xpqoiooisidi d
,'-."/#.(% d// si
pqoiooiq0si kdi os
k/ivik s/s
(dos/sodikqd
piv/ s 0spdsid)
N / O
Grade B and Level 3
ZcoudAikq Aci1oupyd Fuvdikv kdi
Avpv

D(,)83) No.Items =57,67893) !/:%/9) B7':&78#0 !%)78E#83) F.&20
DISF 25 C/' C/' C/' C/'

GRISS 28 C/' C/' C/' C/'

CSFQ 14 C/' C/' C/' C/'

N / O
Female Sexual Function Index
(FSFI)
! Desire,
! Arousal,
! Lubrication,
! Orgasm,
! Satisfaction
! Pain
Total score- overall sexual function
19 items

M9)' 9"($'#*#'(0)+ $) 212 )3%.)4!

N
gold standard measure of
female sexual dysfunction for
outcome and diagnostic studies in
FSD (Sand, 2009)

Grade A and Level 1
Sexual Function Questionnaire
(SFQ)
! Desire,
! Arousal-sensation,
! Arousal-lubrication,
! Arousal-cognitive,
! Orgasm,
! Enjoyment,
! Pain
26 items,(also 34 and 7 items)
Cut-scores ypqoionov1di o cvciq 1nou ocoudAikq
uoAci1oupyid
Grade B and Level 3
N
Female Sexual Distress Scale
(FSDS)
! J+/ <-# ?'5$./$(
! 12 items
! J)."5)' !"#$%&'& (distress) /*< $)6#=/3',< *"<>3(/
! cut-off score > 15 *"#.)+-)./' 84 %-?)'6( )-<93($(4
Grade B and Level 3
N

Sexual Interest and Desire Inventory Female
(SIDI-F)
! I/./$,)=5$.(,) &'/ -/ )."5)' .(- /-./*<,"'$( $) 0)"/*)+/ &'/ GFH7 $) *"#-
)(-#*/=$'/,%4 &=-/+,)4
! 13 items
! P?'/'.)"<.(.5 .#= <.' )."5)' '()*+#,&,* -*. '/$"#,&,*
Grade C and Level 4
N
Hypoactive Sexual Desire Disorder
Screener
! 7"&/3)+# ?'/3#&14 &'/ GFH7 (screener)
! 4 items
! I/./$,)=5$.(,) &'/ )./- )(-#*/=$'/,%4 &=-/+,)4
! Total Score < 7 =*#?(3:-)' GFH7
Grade C and Level 4
N
Decreased Sexual Desire Screener
(DSDS)
! 7"&/3)+# ?'/3#&14 &'/ GFH7 (screener)
! 5 items
! I/./$,)=5$.(,) &'/ *"# ,/' )./- )(-#*/=$'/,%4 &=-/+,)4

Grade C and Level 4
N

D(,)83) No.Items =57,67893) !/:%/9) B7':&78#0 !%)78E#83) F.&20
FSFI 19 C/' C/' C/' C/'

SFQ 26 C/' C/' C/' C/'

FSDS 12 C/' C/' C/' C/'

SIDI-F 13 C/' C/' D9' C/'

HSDD 4 C/' C/' D9' C/'

DSDS 5 C/' C/' D9' C/'

N
ZcoudAikq Aci1oupyd Avpv
International Index of Erectile
Function (IIEF)
! Quality of sexual function
! 15 items (short 5 items)

F*#- ,3+/,)4, <9' total score
! erectile function,
! orgasmic function,
! sexual desire,
! sexual satisfaction,
! overall satisfaction
tyci ypqoionoiq0ci oc
ndvo dn 50 kAivikc
cAc1c
dno1cAcod1ik1q1d
(Rosen, 2002)
Hdvo dn 60 cAc1c
cyouv 1ckqpiooci 1qv
cudio0qoid 1ou cpydAciou
o1d 0cpdncu1ikd
dno1cAcod1d!
(Rosen, 2002)
Grade A and Level 1
O
Premature Ejaculation Profile
(PEP)
! 4 items
! M3)&9#4 ),$*)"5.'$(4
! P,/-#*#+($( /*< $)6#=/3',1 )*/21
! 7-<93($( (distress) /*< ),$*)"5.'$(
! ?'/*"#$8*',1 ?=$,#3+/ $9).',1 ) ),$*)"5.'$(
Total score
Grade C and Level 3
O
Avpc c ydqAd
okop ciydv IELT< 2
min!
Xpqoionoici1di o
cpydAcio c1pqoq
dno1cAcod1ik1q1d
0cpdncid.
Index of Premature Ejaculation
(IPE)
! 10 items
! H)6#=/3',1 ',/-#*#+($(,
! M3)&9#4 ),$*)"5.'$(4
! 7-<93($( (distress) /*< &"1&#"( ),$*)"5.'$(.
YqqAq
ouoyc1ioq c
IELT!
O
Grade C and Level 4
Xpqoionoici1di o
cpydAcio c1pqoq
dno1cAcod1ik1q1d
0cpdncid.
Premature Ejaculation Diagnostic
Tool (PEDT)
! 7"&/3)+# ?'/3#&14 (screener)
! 5 items
! G'/3#&1 $B28-/ ) ,"'.1"'/ DSM-IV

! E*#=$+/ )3%&9#=,
! $=9-<.(./,
! )359'$.# )")0'$<,
! )-<93($(
! ?'/*"#$8*',1 ?=$,#3+/

! score >11 *'0/-1 !7I
Grade C and Level 4
O
Male Sexual Health Questionnaire
(MSHQ)
! 25 items
! $.B$(
! ),$*)"5.'$( (7items)
! $)6#=/3',1 ',/-#*#+($(
! dnouoid ckoncpd1ioq,
! kd0uo1cpqoq ckoncpd1ioq,
! opq ckoncpd1ioq,
! noo1q1d oncpd1o,
! ikdvonoiqoq dn
ckoncpd1ioq,
! nvo kd1d ckoncpd1ioq
Short form-4
items on
ejaculation
Grade B and Level 3
O
ZcoudAikq Aci1oupyd Avpv

D(,)83) No.Items =57,67893) !/:%/9) B7':&78#0 !%)78E#83) F.&20
IIEF 15 C/' C/' C/' C/'
PEP 4 C/' C/' C/' D9'
IPE 10 C/' C/' D9' C/'
PEDT 5 C/' C/' D9' C/'
MSHQ 4 C/' C/' C/' D9'
KAdkc Ano1cAcod1ik1q1d kdi
Hoi1q1d Zq
Treatment Satisfaction Scale (TSS)
! J)."5)' .(- $)6#=/3',1 ',/-#*#+($( /-?":- ) !"1"%*2 $1!3-%"41.'0+ ,/' .8-
$=-."<28- .#=4.
! J)."5)' .(- ',/-#*#+($( /*< .( 0)"/*)+/ $.# *%"/4 .#= 9"<-#=
! 73)B0)"#4 (2/"/,#)0)"/*)+/4 /$0)-14 ,/' $B-."#2#4, =*< 0)"/*)+/ /$0)-14
,/' $B-."#2#4.
! spontaneity, quality of erection, quality of ejaculation, quality of orgasm, sexual
pleasure, and confidence.
! reliability of treatment, convenience, treatment efficacy, conformity to treatment
expectations, overall satisfaction and intentions for continued use of the particular
drug.
Grade B and Level 3
Sexual Life Quality Questionnaire
(SLQQ)
! 16 items
! sexual quality of life
! treatment satisfaction
! H=&,"+-)' .(- */"#B$/ $)6#=/3',1 )*)'"+/ .8- /-?":- 1 ,/' $=-."<28- .#=4
) ),)+-( *"# .(4 89%97:;0 B%8-279,%&/3)0
Grade C and Level 4
Erectile Dysfunction Inventory for
Treatment and Satisfaction (EDITS)
! AioAoyci 1qv ikdvonoiqoq dn 0cpdncid yid ZA kdi icpcuvd 1qv
cnipdoq 1q ikdvonoiqoq 1ou do0cvo kdi 1q ouv1pqou o1q
ouvcyioq 1q 0cpdncid.
! HoAAdnAdoid(ouc 1ov coo po X 25= 0-100
$ ZuvoAikq ikdvonoiqoq
$ Av 0cpdnci d dv1dnokpi 0qkc o1i
npoookic
$ Hi0dv1q1d ouvcyioq 0cpdncid
$ EukoAid ypqoq
$ Ikdvonoiqoq dn dpyikq pdoq
$ Ikdvonoiqoq dn idpkcid pdoq
$ Enipdoq o1q ocoudAikq du1oncnoi0qoq
$ Ikdvonoiqoq ouv1pqou dn 0cpdncid,
$ Ouoik1q1d o1oq kdi okAqp1q1d
$ ZuvoAikq ikdvonoiqoq
$ Av 0cpdncid dv1dnokpi0qkc o1i
npoookic
$ Enipdoq o1qv dio0qoq ouv1pqou 1i
civdi cni0uq1q
$ Ikdvonoiqoq dn idpkcid pdoq
$ Ho dio0dvc1di q ov1poqo yid 1q
ouvcyioq 1q 0cpdncid
Grade B and Level 2
Self-Esteem And Relationship
(SEAR)
! E6'#3#&)+ .(- )*+?"/$( .(4 $.=.',14 ?=$3)'.#="&+/4 $.(- /=.#*)*#+0($( ,/'
$)6#=/3',1 $9%$(
! 14 items= 8 items sexual relationship satisfaction + 6 items confidence

Grade A and Level 2
O
Psychological and Interpersonal
Relationship Scale (PAIRS)
! J)."5)' A=9#-,#'-8-',%4 )*'*.:$)'4 .(4 $.=.',14 ?=$3)'.#="&+/4 ,/' .(4
0)"/*)+/4
! 23 items
! H)6#=/3',1 /=.#*)*#+0($(
! E=0#"(.'$<4
! E-($=9+)4 9"<-#=
Grade B and Level 3
O
Sexual Quality of Life Male (SQOL-
M), -Female (SQOL-F)
7*+?"/$( HG 1 !7I $.(-
% E=.#),.+($(
% !#'<.(./ $9%$(4
% H=-/'$0(/.',1 )=)6+/
(11 items)

7*+?"/$( QHG $.(-
% E=.#),.+($(
% !#'<.(./ $9%$(4
% H=-/'$0(/.',1 )=)6+/
(18 items)

Grade B and Level 3 Grade C and Level 4
KAdkc Ano1cAcod1ik1q1d
kdi Hoi1q1d Zq

D(,)83) No.Items G"-, =57,67893) !/:%/9) B7':&78#0 !%)78E#83) F.&20
TSS 19/12 NO C/' C/' C/' C/'
SLQQ 16 NO C/' C/' C/' C/'
EDITS 11/5 NO C/' C/' C/' D9'
SEAR 14 O C/' C/' C/' C/'
PAIRS 23 O C/' C/' C/' C/'
SQOL-M/F 11/18 NO C/' C/' D9' C/'
EPOTHMATA
np{q;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
! 20 29A(, 76 :7-', 1,85
! =6. 9#( $)-)'9), H,79#9;0 89, =I!J (9;)
K-2:9&,-,/3)0)
! L5,B,0 2 9, )89<&7 9,% <9,%0- 8%H,79;9&7' ,%
6,% ;9)( 6'(9) 9, DF!JMD ,%,
! )--' 9#( 6&A9# H,&' 9) <+)8) /7)93 B2( 9,
63892%)!
! L:9,92 4 H,&<0 B2( ,% 8#:AE#:2
! D"92 () )%()(789A B2( E<->!
! L&+29)7 89, /&)H23, 8)0 :)7 B#-A(27: 23)7 +'-7),
:)7 <+)8) 9#( 2%:)7&3) 9#0 N>;0 ,% :)7 </7()
&.6)
O HcpikAq
O HcpikAq ounAqpvci 1o IIEF
!1: ?.8, 8%+(' 23+20 89"8# :)9' 9# B7'&:27) ,6,7)8B;6,92 825,%)-7:;0 B&)89#&7.9#9)0 (/=-/-'$#B, )*/214);
0 = ?)- )+9/ $)6#=/3',1 ?"/$.("'<.(./
1 = $9)?<- *#.% / *#.%
2 = 3+&)4 2#"%4 (*#3B 3'&<.)")4 /*< .'4 '$%4)
3 = )"',%4 2#"%4 (*)"+*#= .'4 '$%4)
4 = .'4 *)"'$$<.)")4 2#"%4 (*#3B *)"'$$<.)")4 /*< .'4 '$%4)
5 = $9)?<- *5-./ / *5-./
!2: $)9' 9# B7'&:27) 825,%)-7:," 2&2E78,", 6.8, 8%+(' 6<9%+20 89"8270 9.8, 8:-#&<0 6,% 8,% 26<9&26)( B7238B%8#;
0 = ?)- )+9/ $)6#=/3',1 ?"/$.("'<.(./
1 = $9)?<- *#.% / *#.%
2 = 3+&)4 2#"%4 (*#3B 3'&<.)")4 /*< .'4 '$%4)
3 = )"',%4 2#"%4 (*)"+*#= .'4 '$%4)
4 = .'4 *)"'$$<.)")4 2#"%4 (*#3B *)"'$$<.)")4 /*< .'4 '$%4)
5 = $9)?<- *5-./ / *5-./
!3: O9)( 6&,86'E#820 () <&E270 82 825,%)-7:; 26)H;, 6.8, 8%+(' :)9'H2&20 () B7278B"8270 (6270);
0 = ?)- *"#$*50($/ $)6#=/3',1 )*/21
1 = $9)?<- *#.% / *#.%
2 = 3+&)4 2#"%4 (*#3B 3'&<.)")4 /*< .'4 '$%4)
3 = )"',%4 2#"%4 (*)"+*#= .'4 '$%4)
4 = .'4 *)"'$$<.)")4 2#"%4 (*#3B *)"'$$<.)")4 /*< .'4 '$%4)
5 = $9)?<- *5-./ / *5-./
!4: $)9' 9# B7'&:27) 825,%)-7:;0 26)H;0, 6.8, 8%+(' :)9'H2&20 () B7)9#&;8270 9# 89"8# 8,% 29' 9# B7238B%8#;
0 = ?)- *"#$*50($/ $)6#=/3',1 )*/21
1 = $9)?<- *#.% / *#.%
2 = 3+&)4 2#"%4 (*#3B 3'&<.)")4 /*< .'4 '$%4)
3 = )"',%4 2#"%4 (*)"+*#= .'4 '$%4)
4 = .'4 *)"'$$<.)")4 2#"%4 (*#3B *)"'$$<.)")4 /*< .'4 '$%4)
5 = $9)?<- *5-./ / *5-./
!5: $)9' 9# B7'&:27) 825,%)-7:;0 26)H;0, ;9)( B"8:,-, () B7)9#&;8270 9# 89"8# 8,% <+&7 9#( ,-,:-;&>8# 9#0 26)H;0;
0 = ?)- *"#$*50($/ $)6#=/3',1 )*/21
1 = *5"/ *#3B ?B$,#3#
2 = *#3B ?B$,#3#
3 = ?B$,#3#
4 = 3+&# ?B$,#3#
5 = ,/0<3#= ?B$,#3#
!15: ?.8, 26789,8"(# <+270 89,( 2)%9. 8,% .97 6,&23 () 629"+27 :)7 () B7)9#&;827 3) 89"8#;
1 = *#3B 9/(31 / ,/0<3#=
2 = 9/(31
3 = %."'/
4 = =A(31
5 = *#3B =A(31

IIEF Erectile Dysfunction domain score
0
5
10
15
20
25
30
E
F

D
o
m
a
i
n

S
c
o
r
e

NORMAL
MILD
MILD TO MODERATE
MODERATE
SEVERE
11
17
22
26
EPOTHMATA
np{q;
9. Hopryo 1
10.Hopryo 2
11. Hopryo 3
H Ivvd o1o yid1p
! Iodvvd 47 c1ov qoio
undAAqAo, (ov1oyqpd, ydAdp life
style
! Eni1cAou yvopiod 1ov Mdpko 32
c1ov nou 1ov dydno kdi cv nopo
yopi du1v!
! Acv cyo dpkc1q cni0uid! Ho1c cv
ciyd 1o udA ou ouvcycid o1o
oc! Mid qopd o1i 2 codc ou
q1dv ndv1d dpkc1, dAAd 1opd cv
q1dvci.
! Mc cvoyAci noA, c o1cvdyopci kdi
0d q0cAd vd duq0ci q cni0uid
ou.
! Acv ndipvo qdpdkd, dAkooA, o1c
cyo kdnoid nd0qoq.
! TcAcu1did cyo kdi cdqci kdi
id1dpdyc o1q ncpioo.
! Kd1d 1d dAAd cido1c kdAd
ocoudAikd
HAqpci 1d kpi1qpid yid 1q idyvooq 1q ycvikcucvq
cu1cpoycvo Aid1dpdyq Mciocvq ZcoudAikq
Eni0uid; NAI q OXI
EPOTHMATOAOFIO MEIOMENHZ ZEEOYAAIKHZ EHIOYMIAZ DSDS

1. zo nopc\0ov, qov o cntnco q ocouo\tkq oo cnt0uto q ou cvtocpovo ko\o kot tkovonotqtko yto co,
Ct not
2. Lct unpct ctuoq oo cntnco q ocouo\tkq oo cnt0uto q cvtocpovo,
Ct not
3. zo cvo\ct o ctucvo cntnco q ocouo\tkq oo cnt0uto q cvtocpovo,
Ct not
4. Co 0c\oc vo ouq0ct o cntnco q ocouo\tkq oo cnt0uto q cvtocpovo,
Ct not
3. opoko\u vo oqctuocc o\ou ou nopyovc nou oto0vcoc ot nopct vo ou\\ouv oqv nopouoo ctuoq
q ocouo\tkq oo cnt0uto q cvtocpovo:

A) Mto ctpoupytkq cncooq, ko0\tq, pouotoot q \\q toptkq kooooq Ct not
8) poko, vopkutk q o\koo\ nou \ovcc upo Ct not
l) Lykuoouvq, npoooo okco, ounuoo cqvonouoq Ct not
A) A\\o ocouo\tk npo\qoo nou nopct vo ccc (novo, ctucvq tcycpoq q npo\qoo opyooou) Ct not
L) zcouo\tk npo\qoo ou ouvpoou oo Ct not
z) Auoopcokcto c q ocoq oo q o ouvpoo oo Ct not
Z) zpc q konuoq Ct not
Av q do0cvq dndv1qoci OXI oc kdnoid dn 1i cpo1qoci
1 c 4, 11c cv nAqpci 1d kpi1qpid yid 1q idyvooq 1q
ycvikcucvq cu1cpoycvo Aid1dpdyq Mciocvq
ZcoudAikq Eni0uid.
EPOTHMATA
np{q;
9. Hopryo 1
10. Hopryo 2
11. Hopryo 3
O Fivvq
50 ).:-
M"9)./' $.# '/.")+# $/4 ) *"<>3(/
$.=.',14 ?=$3)'.#="&+/4.
I5-)' .# IIEF ) $,#" 11= %."'/ HG
E,#3#=0)+ 0)"/*)+/.
J).5 /*< 3 1-)4 $=$.(/.',14
0)"/*)+/4 )*/-/3/>5-)' .# IIEF )
$,#" 22= 1*'/ HG
=():,7(A(27 .97 E<-27 ()
B7):.P27 970 8%(2B&320 2627B;

=) <+27 67) )62-678923
Q) 23()7 7:)(,6,7#<(,0 )6. 9#
89"8# 9,%
C) E) ):,-,%E;827 '--#
E2&)623) 2 '--,( 8%('B2-H,
IIEF Erectile Dysfunction domain score
0
5
10
15
20
25
30
E
F

D
o
m
a
i
n

S
c
o
r
e

NORMAL
MILD
MILD TO MODERATE
MODERATE
SEVERE
11
17
22
26
Efficacy of PDE5i in general ED populations
HAPAMETPOZ Sildenafil Tadalafil Vardenafil
placebo sildenafil placebo tadalafil placebo vardenafil
IIEF EF Domain 12.2 22.1
(A=9.9)
15.1 23.9
(A=8.8)
14.8 21.8
(A=7)
SEP2
Ikovq okKqptqto
50% 85% 48% 80% 49.1% 89,4%
SEP3
Ikovq pkro
22% 69% 31% 70% 49% 79.1%
GAQ
Frvkq
kovonoqoq
25% 84% 35% 81% 28% 85%
Hatzimouratidis K and Hatzichristou DG. Drugs 2005, 65:1621-1650
Ano1cAcod1ik1q1d 1v dvdo1oAcv 1q
qoqoico1cpoq 1nou 5

18.12.13 Kirana (SCALESVaidakis)

Încărcat de

Informații document

Titlu original

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

18.12.13 Kirana (SCALESVaidakis)

Încărcat de

Drepturi de autor:

Formate disponibile

KAdkc kAivikq ck1qoq 1q

S-ar putea să vă placă și